1419 related articles for article (PubMed ID: 20056126)
21. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition.
Winter CC; Gumperz JE; Parham P; Long EO; Wagtmann N
J Immunol; 1998 Jul; 161(2):571-7. PubMed ID: 9670929
[TBL] [Abstract][Full Text] [Related]
22. Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining.
Falco M; Romeo E; Marcenaro S; Martini S; Vitale M; Bottino C; Mingari MC; Moretta L; Moretta A; Pende D
J Immunol; 2010 Jul; 185(1):433-41. PubMed ID: 20525888
[TBL] [Abstract][Full Text] [Related]
23. CD8-interaction mutant HLA-Cw3 molecules protect porcine cells from human natural killer cell-mediated antibody-dependent cellular cytotoxicity without stimulating cytotoxic T lymphocytes.
Sharland A; Lee JH; Saidman S; Waneck GL
Transplantation; 2003 Dec; 76(11):1615-22. PubMed ID: 14702534
[TBL] [Abstract][Full Text] [Related]
24. Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism.
Avril T; Jarousseau AC; Watier H; Boucraut J; Le Bouteiller P; Bardos P; Thibault G
J Immunol; 1999 May; 162(10):5902-9. PubMed ID: 10229826
[TBL] [Abstract][Full Text] [Related]
25. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro.
Rose MJ; Brooks AG; Stewart LA; Nguyen TH; Schwarer AP
J Immunol; 2009 Oct; 183(7):4502-8. PubMed ID: 19748981
[TBL] [Abstract][Full Text] [Related]
26. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
28. Expression of NK cell receptors on decidual T cells in human pregnancy.
Tilburgs T; van der Mast BJ; Nagtzaam NM; Roelen DL; Scherjon SA; Claas FH
J Reprod Immunol; 2009 Jun; 80(1-2):22-32. PubMed ID: 19394706
[TBL] [Abstract][Full Text] [Related]
29. NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells.
Kurago ZB; Lutz CT; Smith KD; Colonna M
J Immunol; 1998 Feb; 160(4):1573-80. PubMed ID: 9469412
[TBL] [Abstract][Full Text] [Related]
30. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
31. Resistance against natural killer cell cytotoxicity: analysis of mechanisms.
Hasenkamp J; Borgerding A; Wulf G; Uhrberg M; Jung W; Dingeldein S; Truemper L; Glass B
Scand J Immunol; 2006 Oct; 64(4):444-9. PubMed ID: 16970688
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
33. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
[TBL] [Abstract][Full Text] [Related]
34. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
35. Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors.
Hasenkamp J; Borgerding A; Uhrberg M; Falk C; Chapuy B; Wulf G; Jung W; Trümper L; Glass B
Scand J Immunol; 2008 Mar; 67(3):218-29. PubMed ID: 18226015
[TBL] [Abstract][Full Text] [Related]
36. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
[TBL] [Abstract][Full Text] [Related]
38. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
39. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection.
Charoudeh HN; Terszowski G; Czaja K; Gonzalez A; Schmitter K; Stern M
Eur J Immunol; 2013 Feb; 43(2):480-7. PubMed ID: 23161492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
